The Paracetamol IV Market is driven by rising healthcare costs"
The paracetamol IV market has seen significant growth in recent years as intravenous administration of paracetamol, also known as acetaminophen, provides a safer and more effective pain relief option compared to oral administration. Paracetamol IV is an analgesic used to relieve mild to moderate pain. It works by blocking prostaglandins, which are compounds in the body that can sensitize nerve endings and cause pain. Paracetamol IV helps bring down fever as well. With advantages such as rapid onset of action within 10 minutes, predictable pharmacokinetics and not requiring stomach emptying for absorption, Paracetamol IV has emerged as a preferred solution among patients and healthcare providers.
Global paracetamol IV market is estimated to be valued at USD 838.1 Mn in 2024 and is expected to reach USD 1,054.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031.
Key Takeaways
Key players operating in the paracetamol IV are Cipla Ltd., Biomed Pharmaceuticals, Vega Pharma Ltd., Chemist Direct, Ascot Pharmaceuticals, Mallinckrodt Pharmaceuticals, Viatris, Inc., Endo International, Reyoung Pharmaceutical Co., Ltd.
Secondly, rising healthcare costs are propelling the demand for Paracetamol IV Market Trends as it provides faster and more effective pain relief compared to oral paracetamol, helping reduce hospital stays and healthcare expenditure. Chronic diseases like a
The paracetamol IV market has seen significant growth in recent years as intravenous administration of paracetamol, also known as acetaminophen, provides a safer and more effective pain relief option compared to oral administration. Paracetamol IV is an analgesic used to relieve mild to moderate pain. It works by blocking prostaglandins, which are compounds in the body that can sensitize nerve endings and cause pain. Paracetamol IV helps bring down fever as well. With advantages such as rapid onset of action within 10 minutes, predictable pharmacokinetics and not requiring stomach emptying for absorption, Paracetamol IV has emerged as a preferred solution among patients and healthcare providers.
Global paracetamol IV market is estimated to be valued at USD 838.1 Mn in 2024 and is expected to reach USD 1,054.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031.
Key Takeaways
Key players operating in the paracetamol IV are Cipla Ltd., Biomed Pharmaceuticals, Vega Pharma Ltd., Chemist Direct, Ascot Pharmaceuticals, Mallinckrodt Pharmaceuticals, Viatris, Inc., Endo International, Reyoung Pharmaceutical Co., Ltd.
Secondly, rising healthcare costs are propelling the demand for Paracetamol IV Market Trends as it provides faster and more effective pain relief compared to oral paracetamol, helping reduce hospital stays and healthcare expenditure. Chronic diseases like a
06:30 AM - Dec 05, 2024 (UTC)
